• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 8, 2024
Emerging Company Profile

Avicenna: Using machine learning to skip the hit-to-lead phase

Seeded by DCVC Bio, Avicenna’s machine learning tech is designed to find a clinical candidate in a haystack of theoretical compounds
Read More
BioCentury | Nov 18, 2019

Tyrosine kinase inhibitors for the treatment of pemphigus

Read More
BioCentury | Jan 18, 2018
Emerging Company Profile

Computing brain entry

How 1st Biotherapeutics is applying computational tools to CNS drug discovery
Read More
BioCentury | Dec 1, 2017
Company News

1ST Bio partners with Neuraly for PD

Read More
BioCentury | Nov 10, 2017
Product R&D

Blueprint gets the GIST

How Blueprint’s BLU-285 targets mutant kinases resistant to front-line drugs
Read More
BioCentury | May 26, 2017
Clinical News

Team identifies potential target pathway for ALS

Read More
BioCentury | Apr 13, 2017
Targets & Mechanisms

Allosteric en-ABL-ement

Why Novartis is combining allosteric and catalytic site ABL inhibitors in CML
Read More
BioCentury | Dec 13, 2016
Distillery Therapeutics

Hepatic

Read More
Items per page:
1 - 8 of 8